

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072092 A1

(51) International Patent Classification⁷: **A61K 31/44**

(21) International Application Number: PCT/US02/07256

(22) International Filing Date: 8 March 2002 (08.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/274,349 8 March 2001 (08.03.2001) US

(71) Applicants: **UNIVERSITY OF KENTUCKY** [US/US];
Research Foundation, 207 Administration Building, Lexington, KY 40506 (US). **UNIVERSITY OF ARIZONA** [US/US]; 2509 N. Campbell Avenue, Tucson, AZ 85719 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: **JACOBSON, Elaine**; University of Arizona, 2509 N. Campbell Avenue, Tucson, AZ 85719 (US). **JACOBSON, Myron, K.**; University of Arizona, 2509 N. Campbell Avenue, Tucson, AZ 85719 (US). **KIM, Hyuntae**; University of Arizona, 2509 N. Campbell Avenue, Tucson, AZ 85719 (US).

(74) Agent: **HANSON, Norman, D.**; Fulbright & Jaworski L.L.P., 666 Fifth Avenue, New York, NY 10103 (US).

(54) Title: METHOD FOR INCREASING LEPTIN LEVELS USING NICOTINIC ACID COMPOUNDS

(57) Abstract: The invention relates to the use of nicotinic acid and nicotinic acid esters, such as nicotinic acid alkyl esters, to increase the amount of leptin in a subject. As a result, one can treat conditions, such as conditions characterized by wounds, by administering sufficient amounts of nicotinic acid or nicotinic acid ester to increase leptin levels to alleviating amounts. Various conditions and modes of treatment are disclosed.

WO 02/072092 A1

METHODS FOR INCREASING LEPTIN LEVELS USING NICOTINIC ACID COMPOUNDS

RELATED APPLICATION

5 This application claims priority of provisional application 60/274,349, filed March 8, 2001, incorporated by reference.

FIELD OF THE INVENTION

10 The invention relates to the use of niacin derivatives and niacin in the regulation of leptin modulated pathways. Specifically, niacin and its derivatives, such as nicotinate esters, lauryl nicotinate ester in particular, stimulate production of leptin, with ramifications as discussed *infra*.

BACKGROUND AND PRIOR ART

15 Leptin, a 167 amino acid protein encoded by the ob gene, was identified in the course of research in identifying molecular defects in an obesity prone strain, *i.e.*, the "ob/ob" mouse. It has been found that leptin is produced for the most part in white adipose tissue, with very small amounts being found in brown adipose tissue. Exemplary of the patent literature relating to this molecule are U.S. Patent Nos. 6,132,724; 6,124,448; 6,124,439; 20 6,068,976; 6,048,837 and 5,795,909, all of which are incorporated by reference.

 The first reports on leptin suggested that it was an adipocyte derived, signaling molecule, which limited food intake and increased energy expenditure, *i.e.*, an "adiposat." The evidence supporting this included observed decreases in body weight, and improved metabolic control in rodents that evidenced genetic or diet induced obesity that were injected 25 with leptin. In the case of ob/ob mice, which have mutations in the ob gene, leading to synthesis of defective leptin molecules that are degraded intracellularly, the effect of leptin is especially pronounced. The ob/ob mice are obese, diabetic and sterile, and exhibit reduced activity, metabolism, and body temperature. In addition, leptin-deficient ob/ob mice suffer from seriously delayed wound healing. Systemic or topically administered leptin has been 30 shown to improve re-epithelialization of wounds in this model. See Frank, et al., J. Clin. Invest. 106: 501-509 (2000). As such, the ob/ob mouse has been used as a model system for testing drugs for their ability to reverse impaired wound healing.

In addition to the effect on leptin deficient mice, discussed *supra*, leptin markedly promoted re-epithelialization in wild type mice. In addition, STAT 3 and peroxisome-proliferator activated receptor ("PPAR" hereafter), which are the downstream regulators in the leptin pathway, are involved in skin homeostasis. See Komuvres, et al., J Invest. Dermatol 115:361-267 (2000). STAT 3 has been shown to play an essential role in skin remodeling, including hair follicle cycling and wound healing. It is also known that PPAR α activators normalize cell proliferation, including epidermal differentiation, and accelerate the development of the epidermal permeability barrier. See Hanley, et al., J. Clin Inv. 100:705-712 (1997). Recently, it has been demonstrated that PPAR α activators inhibit murine skin tumor promotion. This is consistent with PPAR α having a role in skin physiology. See Thuillier, et al., Mol. Carcinogenesis 29:134-142 (2000).

Further research on leptin has revealed that the molecule alters the transcription of several adipose specific genes involved in lipogenesis, lipolysis, and energy metabolism. It also appears to trigger apoptosis in white adipose tissue. Most of the molecule's metabolic effects appear to result from specific interactions with receptors located in the central nervous system, and in peripheral tissues. The receptor has been identified and is a Class I cytokine receptor that belongs to a family that includes the IL-2 receptor, interferon receptor and growth hormone receptor. In brief, the leptin receptor transmits leptin signal to the three STAT molecules STAT 3, 5, and 6, referred to collectively as the "fat-STATS."

The accepted view of leptin is that its primary role is to prevent obesity via regulating food intake and thermogenesis via action on hypothalamic centers. Recent evidence suggests, however, that leptin may have an additional role, *i.e.*, it may exhibit antisteatotic activity, in that fatty acid over-accumulation in non-adipose tissue may be prevented by leptin mediated regulation of β -oxidation. Leptin increases enzymes involved in fatty acid oxidation and stimulates a previously unobserved form of lipolysis, where glycerol is released without proportional release of free fatty acids.

Various leptin receptor isoforms are expressed throughout the body suggesting that leptin has additional physiological functions on extra-neural tissue. Studies have been carried out to evaluate tissue responsiveness to leptin, via determining what effects, if any, it has on glucidic and lipidic metabolism, as well as expression of some enzymes. If a direct effect of leptin on a given tissue is observed, it implies rapid induction of signal transduction

mechanisms, flowing from hormone/receptor binding. Essentially the mechanism of action can be summarized as follows: leptin activates STAT 3 in adipose tissue, binding of leptin to its receptor leads to receptor oligomerization, and JAK activation, leading in turn to STAT phosphorylation; phosphorylated STATs dimerize and translocate into nuclei, where they activate target genes. In brief:

- (i) Leptin activates STAT 3, and increases PPAR α activity;
- (ii) PPAR α /PPRE induces apo A-I expression in liver cells;
- (iii) STAT3/PPAR α is essential for skin homeostasis;
- (iv) PPAR α activators inhibit mouse skin tumor promotion.

See, e.g. Bendinelli, et al., Mol. Cell Endocrin 168:11-20 (2000); Unger, et al., Proc. Natl. Acad. Sci USA 96:2327-2332 (1992); Peters, et al., J. Biol. Chem. 272:27307-27312 (1997); Hanley, et al., J. Clin. Invest. 100:705-712 (1997); Sano, et al., EMBOJ 18:4657-4666 (1999); Thuillier, et al., Mol. Carcin 29:134-142 (2000).

In addition to playing a role in energy regulation, leptin also regulates endocrine and immune functions. Leptin levels increase acutely during infection and inflammation, and may represent a protective component of the host response to inflammation. Leptin deficiency increases susceptibility to infectious and inflammatory stimuli and is associated with dysregulation of cytokine production. See Faggioni, et al., FASEB J. 15:2565-2571 (2001).

In addition, it can be hypothesized that the pathway described *supra* can also lead to skin homeostasis and remodeling, which in turn leads to epidermal barrier development, wound healing, and hair growth, as well as the inhibition of skin tumor promotion caused by increased immune functions. This is summarized in figure 1.

Niacin is essential to formation of the coenzymes nicotinamide dinucleotide (NAD), and NAD phosphate (NADP), where the nicotinamide moiety acts as an electron acceptor or hydrogen donor in many biological redox reactions. To elaborate, NAD functions as an electron carrier for intracellular respiration, and as a coenzyme in the oxidation of fuel molecules. NADP acts as a hydrogen donor in reductive biosynthesis, including fatty acid and steroid synthesis. As is the case with NAD, it also acts as a coenzyme.

NAD is the substrate for three classes of enzymes that transfer ADP-ribose units to proteins involved in DNA repair, cell differentiation, and cellular calcium mobilization.

Nicotinic acid, in contrast to nicotinamide, when given in doses of 1.5-4g/day improves blood cholesterol profiles.

Acipimox, a commercially available, nicotinic acid analog and hypolipodemic agent, was shown to increase plasma leptin levels in transgenic mice. *See, e.g., Worm, et al., Eur. J. Endocrin* 143:389-395 (2000).

It has been shown that nicotinic acid derivatives have efficacy in, *inter alia*, skin cell protection, DNA repair, etc. *See, e.g., U.S. Patent No. 6,337,065*, filed December 1, 1999 to Jacobson, *et al.*, incorporated by reference in its entirety. This application describes various nicotinic acid derivatives, including a dodecyl, or lauryl nicotinic acid ester. It has now been found that such nicotinic acid esters, such as lauryl nicotinic acid ester, stimulate leptin production to an extent not seen with niacin. As the nicotinic acid esters can be formulated as *e.g., materials suitable for topical application*, a new approach to leptin stimulation and production is provided.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a proposed mechanism and effect pathway believed to operate in the invention. Note a flat line means the target condition is inhibited. Hence, the effect of leptin on skin tumor promotion is inhibition of the tumor.

Figure 2 summarizes data relating to leptin production in adipocytes in vitro.

Figure 3 compares the result of experiments designed to determine the levels of plasma leptin in test animals, after niacin was administered in the form of lauryl nicotinic acid ester.

Figure 4 presents a summary of data generated following the work of example 2, in which serum leptin levels were measured. "NIA 114" is the lauryl ester, while "NIA 112" is the myristyl ester.

Figure 5 summarizes results of experiments designed to show changes in wound size following administration of the nicotinic acid esters.

Figure 6 sets forth parallel results, in which the serum leptin levels of the mice were measured.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS**EXAMPLE 1**

Adipose tissue is recognized as the major source of leptin production in animals. As such, experiments were designed to determine the effect of niacin on leptin production in adipocytes.

Human adipocytes were obtained in accordance with standard methods. In brief, preadipocytes were collected from subcutaneous adipose tissue, following collagenase treatment. The preadipocytes were plated, and allowed to differentiate for 3 weeks, to form adipocytes.

The adipocytes were then incubated, in 0.6 ml of DMEM/F-10 medium, to which 2% bovine serum albumin was added. In addition, cultures either received 0.1 mM niacin, or did not.

After 24 hours, the culture medium was analyzed for leptin, using a commercially available ELISA kit.

The results, which are presented in figure 2, show that in the cultures to which niacin was added, leptin production increased 62%.

EXAMPLE 2

Female apoB/CETP double transgenic mice, obtained from a commercial supplier, were divided into 3 groups, and housed as six animals per cage. One group served as control, and received a standard diet, without added niacin. Backs were shaved, and lotion was applied which was identical to the lotion applied to the third group, as described *infra*, without lauryl nicotinate ester. A second group received niacin, in the form of its sodium salt, dissolved in drinking water at a concentration of 0.75% (0.63% free acid). The niacin intake of the animals was estimated based on water consumption and was approximately 1400 mg/kg of body weight, based upon an estimated consumption of 23 ml of water per 100g of body weight, and an average body weight of 25g. This is equivalent to about 8.4g/day for a 70 kg human. See Freireich, et al., Cancer Chemother. Rep. 50: 219-244 (1966) incorporated by reference. For the third group, backs were shaved, and the lauryl nicotinate ester was applied to shaved areas, via 200 mg of lotion, containing 10% (wt/wt) of the lauryl nicotinate ester. The amount of the ester applied is approximately 80-800

mg/kg, again assuming an average weight of 25g. Using Freireich, *supra*, this is equivalent to a dose from about 0.48 to about 4.8 g/day/70kg human. The lotion was applied daily for 13 weeks.

Leptin levels in plasma were determined using a commercially available murine leptin radioimmunoassay. The RIA was carried out on fasting (16h) blood samples obtained from the retroorbital plexus. The blood samples were collected and centrifuged at 2000xg for 15 minutes to secure plasma. The results, summarized in figure 3, show that oral niacin did increase the amount of circulating leptin, however, the lauryl nicotinate ester surpassed it in terms of the amount of circulating leptin.

EXAMPLE 3

The experiments described in example 2 were continued, in the experiment described in this example. Specifically, male BALB/C mice were shaved, from the scapulae to tail bases. The subject animals then received topical application of the lauryl nicotinate ester lotion, described in example 2, *supra*, or myristyl nicotinate ester lotion, in varying concentrations. Controls received vehicle only. The lotion was applied at a dose of 4 ml/kg/mouse.

Serum leptin levels were measured, as described, *supra*. The results indicate that the serum leptin levels increased by 45% in the subject animals which received the 10% lauryl nicotinate ester lotion, while the increase for subject animals which received myristyl nicotinate ester was 57% (for the 2% formulation), and 77% (for the 5% formulation). Figure 4 presents these results.

EXAMPLE 4

The association of leptin with wound healing was discussed *supra*. This correlation was investigated in these experiments.

Mice were inflicted with full thickness wounds of about 6 mm in diameter, under anesthesia (sodium phenobarbital). They then received topical application of a 20% nicotinate ester lotion, every day, for 14 days. The dosing was 100 μ l for each application, with two applications every day. As a control, the lotion without the ester was used. Wound diameter was measured every day.

The results are presented in figure 5, which shows that the mice which received the nicotinate ester containing formulations showed a reduction of wound thickness, as composed to controls. The lauryl ester was most effective with a 43% reduction.

When the serum leptin levels were measured, the mice which received the nicotinate ester application were found to have an increase of 44% as compared to controls. These results are depicted in figure 6.

The foregoing examples set forth various features of the invention which include, *inter alia*, a method for stimulating production of leptin in a subject in need thereof, by administering to said subject a leptin stimulating amount of a nicotinic acid or nicotinic acid derivative, such as a nicotinic acid ester. Most preferably, this is a lauryl nicotinic acid ester, although other compounds, such as those described in the patent application cited *supra* may also be used. Especially preferred are nicotinic acid per se, or nicotinic acid alkyl esters, where the ester moiety contains from 1-30, optionally substituted, carbon atoms. More preferably, the alkyl moiety contains 1-22 carbon atoms, most preferably 1-18 carbon atoms. The subjects are preferably subjects suffering from a condition that can be alleviated by increased leptin levels, including those set forth in figure 1, improved immune function, skin epitheliation, hair follicle cycling, inhibition of tumor formation, such as skin tumor formation, and so forth.

The mode by which the nicotinic acid or ester is administered to the subject may vary. Oral, time release, intravenous, intradermal, and other forms of administration are contemplated, as topical administration. Such topical administration may be via a creme, lotion, liquid, aerosol, body wash, mouthwash, toothpaste, gavage, or other form of topical administration. For example, in the case of timed released application, "patches," such as the type used in timed release of nicotine, bandages, wraps, and so forth may be employed.

The nicotinic acid ester is administered in an amount sufficient to stimulate leptin production. The dose used can and will vary; however, formulations should deliver, *e.g.*, doses ranging from about 0.1 to about 10g/day/70 kg body weight, more preferably from about 0.1 to about 7g/day/70 kg body weight, most preferably from about 0.4 to about 5g/day/70 kg body weight.

As indicated, *supra*, the stimulation of leptin production can lead, in addition to the effects associated with leptin previously, to regression of skin tumors, skin homeostases and remodeling, epidermal barrier development, wound healing, and hair growth.

Other applications will be clear to the skilled artisan and need not be elaborated
5 herein.

WE CLAIM

1. A method for increasing leptin levels comprising administering to a subject suffering from a condition alleviatable by increased leptin levels, an amount of nicotinic acid or a nicotinic acid ester in an amount sufficient to increase levels of leptin in said subject
5 in an amount sufficient to alleviate said condition.
2. The method of claim 1, comprising administering nicotinic acid to said subject.
3. The method of claim 1, comprising administering a nicotinic acid ester to said subject.
4. The method of claim 3, wherein said nicotinic acid ester is a nicotinic acid alkyl ester,
10 containing a substituted or unsubstituted alkyl chain from 1 to 30 carbon atoms.
5. The method of claim 4, wherein said alkyl chain contains from 1 to 22 carbon atoms.
6. The method of claim 5, wherein said alkyl chain contains from 1 to 18 carbon atoms.
7. The method of claim 4, wherein said nicotinic acid ester contains 12 carbons or 14 carbons.
8. The method of claim 1, comprising administering said nicotinic acid or nicotinic acid
15 ester is administered orally.
9. The method of claim 1, comprising administering said nicotinic acid or nicotinic acid ester is administered topically.
10. The method of claim 1, comprising administering a composition which comprises
20 more than one nicotinic acid ester.
11. The method of claim 1, comprising administering nicotinic acid and at least one nicotinic acid ester.
12. The method of claim 1, wherein said subject is suffering from a skin wound.




Figure 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/07256

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 31/44

US CL :514/356

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/356

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST: uspat, us-pgpub

niacin, nicotinic acid, ester, wound healing, hair growth, leptin, inflammation

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 6,068,976 A (BRIGGS et al.) 30 May 2000, see entire document.	1-12
Y	US 6,015,821 (HORROBIN et al.) 18 January 2000, see col. 1, lines 9-14, col. 2, line 63 to col. 3, line 63, claim 7.	1-12

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

"	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 03 MAY 2002	Date of mailing of the international search report 22 AUG 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer CYBILLE DELACROIX-MUIRHEID Telephone No. (703) 308-1235